ALLO · CIK 0001737287
Allogene Therapeutics, Inc.
What Allogene Therapeutics, Inc. owns has not been researched yet. This page is its ownership register, who holds it, and the absence of holdings below means nobody has looked rather than that there is nothing to find.
Allogene Therapeutics, Inc. - Profile
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
- Listed on
- Nasdaq
- Employees
- 152stated 2026
- Financial year ends
- 31 December
Source
Address, industry classification, listing and incorporation come from Allogene Therapeutics, Inc.'s own SEC filer record, so the industry is the SEC's dry classification rather than a marketing label. The headcount is the figure the sources below state for 2026. The description was written for this site in August 2026 from Allogene Therapeutics, Inc. Form 10-K for fiscal year 2025, Allogene Therapeutics, Inc. Form 10-Q for the quarter ended 30 June 2026 and Allogene Therapeutics, Inc. Form 8-K dated 12 August 2026, Exhibit 99.1 (second quarter 2026 results and business update), not taken from any single article.
Share price
ALLO
Description
Allogene Therapeutics, Inc. is a clinical-stage biotechnology company in South San Francisco, California developing allogeneic CAR T cell therapies for cancer and autoimmune disease. Its T cells are engineered from healthy donors rather than from each patient, so doses sit frozen in inventory and can be infused within days, where autologous CAR T needs weeks of individualized manufacturing and up to 31% of intended patients in registrational trials never got treated. Gene editing removes the T cell receptor to limit graft versus host disease, its Dagger technology adds an anti-CD70 CAR to blunt host rejection, and cells are made at its own Cell Forge 1 plant. Lead candidate cemacabtagene ansegedleucel (cema-cel) is in ALPHA3, a pivotal randomized Phase 2 trial of first line consolidation in large B-cell lymphoma patients positive for minimal residual disease: an interim analysis cleared MRD in 58.3% of the cema-cel arm against 16.7% on observation, the FDA granted RMAT and Fast Track in July 2026, and enrollment should finish by end 2027. ALLO-329 is in the Phase 1 RESOLUTION trial in autoimmune disease. Allogene bought these CAR T assets from Pfizer in 2018 and owes it milestones and royalties. Net loss was $190.9 million in 2025 and $85.3 million in the first half of 2026, against $423.6 million of cash at 30 June 2026 and a runway into the first quarter of 2029.
Who owns Allogene Therapeutics, Inc..
Nothing recorded on this side. That is a sourced finding rather than a gap where the research notes say so: see the notes below.
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 204 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
204 managers reported a position, together holding 184.2m shares, or 53.4% of the company. The 40 largest are listed. Percentages are of the 345.2m shares outstanding at 11 May 2026, the count in force when this quarter was measured rather than the count today.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Added 27 Aug 2026 by scripts/promote_discovered.py. This company reached the site because a covered investor holds it, not because an index listed it: it was a position in a portfolio here with no page of its own. The match was proved by requiring the register built for this CIK to contain the same CUSIP the portfolio held.
- Discovered at CUSIP 019770106, held by ameriprise, bank-of-america, blackrock, bny-mellon, citigroup, fidelity-fmr, geode, goldman-sachs, huntington-bancshares, invesco, jpmorgan, metlife, morgan-stanley, mt-bank, northern-trust, pfizer, prudential-financial, raymond-james, state-street, us-bancorp, vanguard, wells-fargo.
- Holdings are NOT researched. The empty holdings list means nobody has looked at what this company owns, not that it owns nothing, and the page says so.
- Shares outstanding and market cap are null rather than guessed. Neither was captured on the dated sweep that carries every other company here.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- Shares outstanding.
- Market capitalisation.